Stock analysts at Maxim Group started coverage on shares of FibroBiologics (NASDAQ:FBLG – Get Free Report) in a report issued on Tuesday, Briefing.com reports. The brokerage set a “buy” rating and a $12.00 price target on the stock. Maxim Group’s price objective points to a potential upside of 334.78% from the company’s previous close.
Separately, EF Hutton Acquisition Co. I raised shares of FibroBiologics to a “strong-buy” rating in a research note on Wednesday, September 4th.
Check Out Our Latest Report on FibroBiologics
FibroBiologics Stock Performance
FibroBiologics (NASDAQ:FBLG – Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09). On average, equities research analysts expect that FibroBiologics will post -0.37 EPS for the current fiscal year.
Institutional Trading of FibroBiologics
Hedge funds have recently made changes to their positions in the company. Transform Wealth LLC bought a new position in FibroBiologics in the 2nd quarter valued at approximately $668,000. ERn Financial LLC acquired a new position in FibroBiologics in the 2nd quarter valued at approximately $159,000. Saxon Interests Inc. bought a new position in shares of FibroBiologics during the second quarter valued at $106,000. RMR Wealth Builders acquired a new position in shares of FibroBiologics during the second quarter worth $186,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of FibroBiologics in the second quarter worth $342,000.
About FibroBiologics
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
See Also
- Five stocks we like better than FibroBiologics
- What is the Euro STOXX 50 Index?
- Workday’s Next-Gen AI Integration: Perfect Time to Buy the Dip?
- Retail Stocks Investing, Explained
- Seize the Growth: Twilio’s AI Innovations Are Driving Huge Upside
- Dividend Payout Ratio Calculator
- Rate Cut Shockwaves: Which Bank Stocks Will Rise or Fall?
Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.